Using 68Ga-PSMA-617 PET imaging for solid cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project monitors the safety profile of 68Ga-PSMA-617 PET imaging in patients with PSMA-expressing solid tumors. It is a single-site, pragmatic, non-randomized, and open-label study that includes all solid tumors expressing PSMA, not just prostate cancer. The study aims to integrate this imaging modality into routine care for better detection and management of eligible cancers, while also assessing its impact on patient management compared to current standards.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor;
2. Patients with suspected, proven or prior tumor expressing PSMA;
3. Informed consent by patient.

Exclusion Criteria:

1. Patient refusal to participate;
2. Prior severe anaphylactic reaction to 68Ga-PSMA-617 .

Where it's running

• Chus
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Éric E Turcotte, MD — Université de Sherbrooke, Centre de Recherche du CHUS
• Study coordinator: Stéphanie Dubreuil
• Email: Stephanie.Dubreuil2@usherbrooke.ca
• Phone: 819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Using a weighted blanket to help cancer patients during IV therapy

  A randomized study tests whether wearing a weighted blanket during IV cancer treatment reduces anxiety, stress, and depression and increases comfort compared with standard blankets.

  Recruiting Sultan Qaboos Comprehensive Cancer Center · Muscat, Seeb · NCT07653035

• JY016 injection for EGFR-positive advanced solid tumors

  This study tests JY016 injections in adults with EGFR-expressing advanced solid cancers to see if it is safe and potentially effective.

  Recruiting Phase 1/2 Biotech Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07510841

• Antibody-armored dendritic cell therapy for people with solid tumors

  This will test a single injection of antibody-armored dendritic cells in adults with certain resected solid tumors after standard adjuvant chemotherapy to see if it is safe and stimulates an immune response.

  Recruiting Phase 1 Shanghai Cell Therapy Group Co.,Ltd · Shanghai · NCT07479667

• Biomarkers and immune responses in early-stage solid cancers treated with immunotherapy

  This study tests immune biomarkers in patients with early-stage solid cancers who are receiving immune checkpoint blockade before surgery.

  Recruiting Institut Claudius Regaud · Toulouse and 2 other locations · NCT07427186

• TCC1727 combined with other cancer medicines for adults with advanced solid tumors

  This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 2 other locations · NCT07371663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.